Tag: phare

Better Practice: 6 months vs 12 months Adjuvant Trastuzumab (Herceptin) in Early Breast Cancer

Better Practice: 6 months vs 12 months Adjuvant Trastuzumab (Herceptin) in Early Breast Cancer

Introduction International guidelines highly recommend adjuvant trastuzumab for breast cancer with HER2+; specifically, immunohistochemistry (IHC 3+, over expression) or fluorescence in situ hybridisation (FISH) amplified affect 20% of all breast cancer cases Addition of 1 year of adjuvant trastuzumab to adjuvant chemotherapy significantly improved disease- free survival (DFS) and overall survival (OS) among women with HER2+ breast … Continue reading Better Practice: 6 months vs 12 months Adjuvant Trastuzumab (Herceptin) in Early Breast Cancer